Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Double-Dose HIV drug may work with TB therapy in small study

NCT ID NCT05630872

First seen Dec 08, 2025 · Last updated May 24, 2026 · Updated 31 times

Summary

This study tested whether taking a double dose of the HIV drug dolutegravir (50 mg twice daily) along with the tuberculosis drug rifapentine is safe and maintains HIV viral suppression. Thirty adults with both HIV and tuberculosis participated. The goal was to see if the higher dose compensates for drug interactions, helping control both diseases.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-ASSOCIATED TUBERCULOSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Durban International CRS (Site # 11201)

    Westridge, Durban RSA, 4091, South Africa

  • South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site # 31793)

    Worcester, Western Province, 6850, South Africa

  • Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site # 31802)

    Bangkok, 6850, Thailand

  • University of Cape Town Lung Institute (UCTLI) CRS (Site # 31792)

    Mowbray, Cape Town, Western Cape, 7700, South Africa

Conditions

Explore the condition pages connected to this study.